Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Bronast - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Bronast

Approved

STANDARD

Bronast

Geofman Pharmaceuticals🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 38a591a1c46c3d1f
Company: Geofman Pharmaceuticals
Type: Standard

Approval Details

Approval Id: 38a591a1c46c3d1f
Drug Approval Philippines Name: Bronast
Product Name: Bronast
Registration Number: DR-XY38938
Brand Name: Bronast
Generic Name: Montelukast (As Sodium)
Dosage Form: Chewable Tablet
Dosage Strength: 5 mg
Manufacturer: Geofman Pharmaceuticals
Importer: Sahar International Trading, Inc.
Distributor: Sahar International Trading, Inc.
Issuance Date: 26 March 2021
Expiry Date: 11 January 2026
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

38a591a1c46c3d1f

Type

Standard

Back to Philippines FDA Approvals